Cervical Cancer Vaccine – Treading Through Past, Present And Future

Cervical Cancer is a serious health problem affecting women globally. It is the third prevalent kind of cancer in women. Nearly 80% of cervical cancer cases are from developing countries where cervical cancer is the second most prevalent reason behind cancer fatalities among women.

The Human Papilloma Virus

The finding that the HPV or Human Papillomavirus virus causes cervical cancer has opened novel avenues in its prevention and treatment. There seems to be a strong association between the occurrence of cervical cancer and the commonness of HPV infection in the populace. Above hundred HPV types has been detected, nearly forty are found to affect the genital region and at least fifteen are deemed oncogenic; 2 other types cause majority of the cases of genital warts.

HPV linked Diseases

Globally, HPV is the most commonly occurring sexually transmitted infection that affects nearly 50-80% women that are sexually active at least once during their life span. Women could usually get infected with HPV in their teen years, twenties or early thirties; however the vast majority clears the virus innately. The progression from HPV infection to cervical cancer is an atypical and gradual progression; nearly five to ten per cent of women infected with oncogenic HPV eventually develop continual infections; these women are at heightened risk of developed high-grade, pre-malignant lesions and if untreated leads to cervical cancer. Usually, it could take about two decades or more for the infections to progress to cancer; hence as a consequence, the incidence of cervical cancer starts to increase after 35-40years of age and does not peak till a woman reaches her fifties or sixties.

HPV vaccine

A vaccine that averts HPV-associated cervical disease –and hence cervical cancer –potentially offers immense benefits. The below stated are the varied cervical cancer vaccination.

• Prophylactic Vaccine
  Prophylactic immunisation offer a potentially economical, logistically simplistic and immensely effectual approach to reducing impediments due to cervical cancer. But, it is not likely to offer any benefits to women who are already infected with HIV-linked diseases.
• Therapeutic Vaccine
  A therapeutic vaccine could be helpful to women that already have the HPV infection. Employed alone or merged with standard treatments, a therapeutic vaccine could aid in averting low-grade ailment from progression and lead to regression of existent lesions; it could additionally have the potential to curb the spread of metastatic cancer and avert relapse of cervical cancer. For maximum efficacy, therapeutic HPV vaccines must elicit cell-intervened immunity as antibodies fail to reach and eradicate the virus once it has been integrated into host cells.
• Chimeric Vaccine
  The most effectual HPV vaccine approach calls for a vaccine that has both prophylactic and therapeutic properties that are present in the chimeric vaccine that has the capacity to prevent novel HPV infections and clearing existent infections. This vaccine could be administered to both sexually inexperienced youngsters and older aged women that have already been infected with HPV. It has a likelihood of having a swifter impact on cervical cancer rates as compared to the purely prophylactic vaccine.
• First-generation VLP Vaccine
  Gardasil (Merck and Co.) and Cervarix (GlaxoSmithKline) are the presently obtainable first-generation VLP vaccinations essentially targeting HPV strains 16 and 18. This is chiefly due to the reason that they are reason behind 70% of squamous cell cervical cancers and an approximate 35% of low grade squamous intraepithelial lesions globally.
  A latest study indicates that HPV 16 and 18 could be accounting for nearly 85% of adenocarcinomas. Epidemiological information indicates that a bivalent vaccine against HPV 16 and 18 could avert an approximate 71% of cervical cancers globally.
  Gardasil additionally targets HPV strains 6 and 11 that lead to 90% of all anogenital warts in both sexes. Judging by the fact that younger aged girls in ages of ten to fifteen years have a comparatively higher immunogenic response as compared to older aged adolescents, vaccine manufacturers are suggesting inoculations at ages of 10-12 years in Europe and North America, where several teens start becoming sexually active early on. In other parts of the world, strong presence of cultural norms govern sexual behaviourisms that could postpone the age of first sexual intercourse till late adolescent year or till after marriage, it could be ideal to inoculate both sexes at a rather later age. Irrespective of the age of first immunisation, inoculation programs must consider the requirement of booster doses.
  Men don main roles in spreading HPV as they do in the case of other sexually transmitted diseases, that indicate that inoculating men could be important for producing herd immunity, even though cervical cancer are known to affect solely the female gender.
• Protein and Peptide Vaccine
  These rely on genetic engineering practices for producing antigenic sections that are capable of evoking an immune response with increased safety and lesser side effects than a whole organism. As they evoke weaker immune responses as compared to the whole pathogen, hence several inoculations are needed for producing long-lasting immunity.
• Recombinant live vector Vaccine
  These vaccines merge the benefits derived from subunit vaccines and live attenuated ones. As they express solely selected HPV genes, hence are rather safe. They are increasingly immunogenic producing long-lasting safeguard with a single vaccination. The disadvantage is that it could be unsafe for immune- compromised individuals.
• DNA Vaccine
  Naked DNA is amongst the latest strategies to vaccine development. Their advantages are that they elicit both cell and antibody-mediated immunity thus inducing long-standing immunity. These could also be stored at room temperatures and have longer shelf life.
• Plant-based Vaccine
  Genes derived from human pathogens are introduced into a range of plants employing genetic engineering. Such transgenic plants then start producing and accumulating disease antigens in their tissues. Optionally, the gene sequences for a required antigen are inserted into either a bacterium or a virus that usually cause infection among plants. When bacterium or virus infection affects adult plants, they manufacture and amass the required proteins. In case edible plants are employed, their fruits and vegetables could have immense potential to function as edible vaccines.

Popularity: 30% [?]